Precipio (PRPO) Q2 2026 earnings summary

Executive summary

• Focused on improving cancer diagnostics through integrated clinical laboratory services and proprietary diagnostic product development, leveraging a dual business model for operational stability and innovation.

• Operates a single segment with two complementary divisions: pathology services (specialized cancer diagnostics) and product development (diagnostic assay kits).

• Achieved record quarterly revenue of $7.0M in Q2 2026, up 24% year-over-year and sequentially from Q1 2026, with positive Adjusted EBITDA of $0.4M.

• Processed 4,652 cases in Q2 2026, up 26% year-over-year; 9,564 cases in the first half of 2026, up 42% year-over-year.

• Cash flow from operations was $0.7M, with quarter-end cash exceeding $3M, up from $1.1M in Q2 2025.

Financial highlights

• Q2 2026 net sales: $7.0M, up 24% year-over-year; six months ended June 30, 2026 net sales: $13.7M, up 30%.

• Q2 2026 gross profit: $3.1M (45% margin), up from $2.4M (43% margin) in Q2 2025.

• Six months gross profit: $5.9M (43% margin), up from $4.6M (43%) in 2025.

• Q2 2026 operating loss: $0.6M; net loss: $0.2M (EPS: -$0.12); six months net loss: $1.7M (EPS: -$0.93).

• Pathology revenue reached $6.1M, up from $6.0M in Q1 2026; product revenue rose to $0.9M from $0.66M in Q1 2026.

Outlook and guidance

• Substantial doubt remains about ability to continue as a going concern over the next 12 months without additional revenue growth or financing.

• Management expressed confidence in continued momentum and operational strength, citing customer growth and improved cash position.

• Ongoing evaluation of the impact of the One Big Beautiful Bill Act of 2025 and macroeconomic/geopolitical risks.